bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Follow-Up Questions
What is the price performance of BMXMF stock?
The current price of BMXMF is $125.34, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Biomerieux SA?
Biomerieux SA belongs to Health Care industry and the sector is Health Care
What is Biomerieux SA market cap?
Biomerieux SA's current market cap is $14.7B
Is Biomerieux SA a buy, sell, or hold?
According to wall street analysts, 16 analysts have made analyst ratings for Biomerieux SA, including 2 strong buy, 9 buy, 6 hold, 1 sell, and 2 strong sell
